T-Therapeutics Ltd
Mateusz Wydro is an experienced professional in the pharmaceutical industry, currently serving as Vice President of CMC and Development at T-Therapeutics Ltd since May 2025. Previously, Wydro held the position of Vice President of CMC at invoX Pharma Limited and spent over a decade at F-star Therapeutics, Inc., where responsibilities included CMC strategy, development of clinical programmes, and successful regulatory submissions. Wydro's career trajectory also includes roles as Senior Director, Director, Principal Scientist, and research fellow in various organizations, showcasing expertise in protein sciences, project leadership, and the management of complex CMC workflows. Wydro earned a Ph.D. in Medical Sciences from Newcastle University and holds additional degrees in Biotechnology.
This person is not in any teams
This person is not in any offices
T-Therapeutics Ltd
T-Therapeutics is a venture-backed company on a mission to unlock the power of T cells to treat chronic and infectious diseases. Based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine, T-Therapeutics has secured significant investment from a blue-chip syndicate of investors to support its drug discovery efforts and prepare candidates for clinical development. T-Therapeutics was founded in 2022, and we are at the very beginning of our journey to develop transformative T cell derived medicines. To realise our ambition, we are currently building facilities, recruiting staff, and establishing our research operations.